Ivermectin Stada

Ivermectin, the active ingredient in Ivermectin Stada, is an anthelmintic presented as an oral formulation for systemic use. It is employed to eliminate a range of parasitic worms and ectoparasites in patients requiring prescription therapy. GNH USA supplies Ivermectin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin Stada acts on a variety of helminth and ectoparasite infections, providing parasitic clearance in affected individuals.

Strongyloidiasis: effective in eradicating Strongyloides stercoralis infection. Onchocerciasis: reduces microfilarial load and prevents disease progression. Scabies: eliminates the Sarcoptes scabiei mite causing intense itching. Pediculosis (lice): clears head and body lice infestations. Other helminth infections: treats a broad spectrum of intestinal nematode infections.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Diarrhoea: loose stools during treatment. - Abdominal pain: cramping or discomfort. - Pruritus: itching at the site of parasite death.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurologic events: seizures, confusion, or ataxia. - Anaphylaxis: acute allergic response requiring emergency care.

Before prescribing Ivermectin Stada, clinicians should consider several safety factors. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: unknown excretion in milk; weigh maternal benefit against infant risk. - Renal or hepatic impairment: dose adjustment may be required. - Concomitant antiparasitics: monitor for additive toxicity. - Strong CYP3A4 inhibitors: avoid or adjust dose to prevent increased exposure. - Store below 25°C: keep in the original container, protect from moisture and light.

Ivermectin may interact with other medicines, necessitating careful review.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): increase systemic exposure. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic efficacy. - Other antiparasitic agents: risk of additive neurotoxicity. - Anticonvulsants: possible alteration of seizure threshold.